Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilucoplan (Zilbrysq) in pediatric AChR antibody-positive generalized myasthenia gravis
2022-502072-23-00Phase 3Authorised
- Sponsor
- UCB
- Start
- Nov 2023
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of zilucoplan in myasthenia gravis (MG), sponsored by UCB. Primary endpoints: Plasma concentrations of zilucoplan at Week 4 (Day 29), Change from baseline in sheep red blood cell (sRBC) lysis at Week 4 (Day 29) and 1 more. Planned start Nov 2023; status: authorised.
02
Drugs
zilucoplan
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2022-502072-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502072-23-00.